IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

Contract Development and Manufacturing of Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing inculding drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

Latest IDT News

Positive interim summary of strategic realignment at CPhl trade fair:

Tuesday, 5. November 2019

IDT Biologika expands portfolio of viral vaccines and biologics more info

IDT Biologika Awarded new Task Order to Manufacture Vaccines and Biologics for Infectious Diseases

Monday, 4. November 2019

IDT Biologika Awarded new Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases more info

IDT Biologika inaugurates new multifunctional production facility for vaccines at BioPharmaPark area

Friday, 5. July 2019

New building for vaccine production enables even more flexible reaction to customer demands more info

Ceva completes acquisition

Wednesday, 3. July 2019

Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split more info

IDT Biologika to concentrate on human vaccines and pharmaceuticals

Wednesday, 5. June 2019

Divestment of animal health business unit enables focus on global growth market more info

Twitter
@IDT Biologika

Thursday, 7. November 2019

IDT Biologika expands portfolio of viral #vaccines and #biologics https://t.co/TMKuYudaND #cphifrankfurt more info

Wednesday, 6. November 2019

RT @MDTechCouncil: Congratulations to #MTCMember: @idtbiologika Awarded New Task Order in the Scope of 10-Year NIH Contract to Manufacture… more info

Wednesday, 6. November 2019

"This major order from the NIAID is another important step in implementing our strategy," CEO Dr. Jürgen Betzing sa… https://t.co/yjdmODq2kA more info

Tuesday, 5. November 2019

IDT Biologika awarded new task order in the scope of 10-Year NIH contract to manufacture #vaccines and #biologics f… https://t.co/WxZNnmdJQY more info

Tuesday, 5. November 2019

RT @CPhIWW: #CPhIWW day 1 in full swing! Are you joining us with the entire pharmaceutical industry in Frankfurt, Germany? https://t.co/g99… more info

Tuesday, 5. November 2019

RT @iitoLifeScience: IDT Biologika expands portfolio of viral vaccines and biologics https://t.co/pYj0kZjl1Q @idtbiologika More Transatlant… more info

Tuesday, 16. July 2019

RT @IMG_ST: Last Friday a multifunctional production facility for human virus production was inaugurated at the #Biopharmapark in #SaxonyAn… more info

Thursday, 6. June 2019

RT @iitoLifeScience: IDT Biologika to Divest Animal Health Business Unit to Focus on Production of Human Vaccines & Medicines https://t.co/… more info

Friday, 17. May 2019

RT @CevaSanteAnimal: [Press Release] 📣 Ceva is proud to announce provisional agreement to acquire the animal health business of biopharmac… more info